GILD Healthcare
Gilead Sciences
| P/E Trailing | -- |
| P/E Forward | -- |
| PEG Ratio | -- |
| Market Cap | -- |
| Price Target | -- |
| D/E Ratio | -- |
| Current Ratio | -- |
| Cash | -- |
| Total Debt | -- |
| Net Cash | -- |
| Gross Margin | -- |
| Operating Margin | -- |
| Net Margin | -- |
| ROE | -- |
| FCF | -- |
| GF Score | -- |
| Altman Z-Score | -- |
| Piotroski F-Score | -- |
| Div. Yield | -- |
| Analyst Rating | -- |
STRONG SELL: Metrics within normal ranges.
Why Gilead Sciences (GILD) Is on Investors’ Radar Today Gilead Sciences (GILD) is drawing investor attention after recent trading left the stock with a 1-day return of about a 1% …
Gilead Sciences is expected to release its fiscal fourth-quarter earnings soon, and analysts project a decline in EPS.
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
US authorities accuse a former Lazard banker of tipping health-care mergers that generated about $41 million in illegal profits.
Speaking at the J.P. Morgan Healthcare Conference 2026, CEO Daniel O’Day said that the company has seven pipeline drugs for HIV.
In the most recent trading session, Gilead Sciences (GILD) closed at $122.59, indicating a +1.23% shift from the previous trading day.
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most undervalued blue chip stocks to buy now. On January 7, 2026, reports highlighted that analysts are increasingly confident in Gilead Sciences, …
On January 6, 2026, OncoNano Medicine announced a research collaboration with Gilead Sciences to test its ON-BOARD encapsulation technology with a Gilead drug candidate, with OncoNano eligible for upfront, milestone …
If you are wondering whether Gilead Sciences is fairly priced or offering value right now, this article will walk through what the numbers actually say about the stock. The share …
BofA raised the firm’s price target on Gilead (GILD) to $154 from $144 and keeps a Buy rating on the shares. The firm, which switched its valuation method, says the …